SCHEMBL3290355

SCHEMBL3290355

CC(=O)OCC(=O)c1cnc(NC(=O)C(C)(C)C)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
CNR2 P34972 1/20 0.36
CHEK1 O14757 1/20 0.35
ALDH1A1 P00352 2/20 0.35
NOTUM Q6P988 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
KDR P35968 1/20 0.33
TP53 P04637 1/20 0.33
PAX8 Q06710 1/20 0.33
KLF5 Q13887 1/20 0.33
GRIN2B Q13224 1/20 0.32
ABL1 P00519 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445808 0.85 CNR2 (0.36) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL3290356 0.82 ALDH1A1 (0.35) SMN1; SMN2CHEK1ALDH1A1MAPK1L3MBTL1
SCHEMBL1445669 0.82 CNR2 (0.34) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL1445413 0.81 CNR2 (0.39) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL3297481 0.80 CNR2 (0.38) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL3290978 0.80 KDR (0.38) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL2644678 0.79 L3MBTL1 (0.41) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL3291100 0.78 CCNB2 (0.36) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL3293626 0.77 MAPK1 (0.44) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1
SCHEMBL1445798 0.74 MEN1 (0.36) NPC1RAB9ASMN1; SMN2CNR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
EP-2145012-A2 MICROBIAL REDUCTION OF AN ACETOXYKETONE F. Hoffmann-Roche AG (CH) 2010-01-20 EP disclosed
WO-2008122511-A2 PROCESS FOR PREPARING 2-AMINO- [5-(1(S), 2-DIHYDROXYETHYL) OR - (KS) -HYDROXY-2-HALOETHYL) ] -PYRAZINE DERIVATIVES BY ENZYMATIC REDUCTION OF THE CORRESPONDING KETONES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-16 WO disclosed
WO-2008122511-A2 PROCESS FOR PREPARING 2-AMINO- [5-(1(S), 2-DIHYDROXYETHYL) OR - (KS) -HYDROXY-2-HALOETHYL) ] -PYRAZINE DERIVATIVES BY ENZYMATIC REDUCTION OF THE CORRESPONDING KETONES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-16 WO disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE GCK, HK2, GCKR NPC1 4710/4885RAB9A 4236/4885SMN1; SMN2 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.